Literature DB >> 19106714

Therapy and clinical trials: management of diabetic dyslipidemia.

Ishwarlal Jialal, Mandeep Bajaj.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19106714      PMCID： PMC2662848          DOI： 10.1097/MOL.0b013e32832210b0

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN： 0957-9672            Impact factor:   4.776


× No keyword cloud information.
  12 in total

Review 1.  Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.

Authors:  John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum
Journal:  J Am Coll Cardiol       Date:  2008-04-15       Impact factor: 24.094

2.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Authors:  B G Brown; X Q Zhao; A Chait; L D Fisher; M C Cheung; J S Morse; A A Dowdy; E K Marino; E L Bolson; P Alaupovic; J Frohlich; J J Albers
Journal:  N Engl J Med       Date:  2001-11-29       Impact factor: 91.245

3.  Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

Authors:  Robert H Knopp; Michael d'Emden; Johan G Smilde; Stuart J Pocock
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

4.  Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.

Authors:  Franklin J Zieve; Marcia F Kalin; Sherwyn L Schwartz; Michael R Jones; William L Bailey
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

5.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors:  A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

6.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 8.  Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.

Authors:  Armin Steinmetz
Journal:  Diabetes Metab Res Rev       Date:  2008 May-Jun       Impact factor: 4.876

Review 9.  The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes.

Authors:  Dean G Karalis
Journal:  Clin Cardiol       Date:  2008-06       Impact factor: 2.882

10.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

Authors:  P M Kearney; L Blackwell; R Collins; A Keech; J Simes; R Peto; J Armitage; C Baigent
Journal:  Lancet       Date:  2008-01-12       Impact factor: 79.321
View more
  4 in total

1.  Bile acid sequestrants and diabetes: introduction and overview to the supplement.

Authors:  I Jialal
Journal:  Metab Syndr Relat Disord       Date:  2010-10-25       Impact factor: 1.894

Review 2.  Management of hypertriglyceridemia in the diabetic patient.

Authors:  Ishwarlal Jialal; William Amess; Manpreet Kaur
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

3.  Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis.

Authors:  Ishwarlal Jialal; Stacey L Abby; Soamnauth Misir; Sukumar Nagendran
Journal:  Metab Syndr Relat Disord       Date:  2009-06       Impact factor: 1.894

4.  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2011-02-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.